{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"acute graft vs. host disease (aGVHD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"chronic graft vs. host disease (cGVHD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Graft versus Host Disease (GVHD) is a frequent complication of allogeneic bone marrow transplant in which the engrafted donor cells attacks the patient's organs and tissue. Acute GVHD (aGVHD) usually occurs during the first three months following an allogeneic BMT. Chronic GVHD (cGVHD) usually develops after the third month post-transplant. Patients may experience one, both or neither.","groups":[{"description":"Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","id":"OG000","title":"Treosulfan and Fludarabine Conditioning"}],"paramType":"NUMBER","populationDescription":"For graft failure 2 of the 60 patients were not evaluable because they exeperienced another event (relapsed) before they could be evaluable for graft failure.","reportingStatus":"POSTED","timeFrame":"42 days","title":"Number of Patients Experiencing Graft Failure","type":"PRIMARY","unitOfMeasure":"participants"}